Rob Dillard

Lung Cancers Today

Patients living in rural areas or who are on Medicaid or uninsured are less likely to receive chemotherapy <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/novel-agent-tislelizumab-extends-survival-in-lung-cancer-interim-phase-iii-report/">for</a> non-small cell lung cancer (NSCLC), according to a <a href="https://www.annalsthoracicsurgery.org/article/S0003-4975(20)30052-7/fulltext">study published</a> in The Annals of Thoracic Surgery.In a retrospective study, researchers collated data on NSCLC patients with pathologic N1 (pN1) disease pN1 disease from the National Cancer Database. The found that of almost 15,000 patients who underwent resection for pN1 disease, only slightly more than half (54.1%) received any chemotherapy.The study results also showed that the benefit of receiving chemotherapy in this patient population is higher than generally thought. Previous research showed that patients with pN1 disease treated with both surgery and chemotherapy increase their five-year cancer survival rate by 5.4% over those who receive only surgery. Researchers of this study found that the survival rate actually increases by 14% &ndash; almost triple the accepted number.&ldquo;This study shows that inequalities exist when it comes to getting the highest level of care,&rdquo; says&nbsp;<a href="https://providers.keckmedicine.org/provider/Elizabeth+Ashleigh+David/728771">Elizabeth A. David</a> MD, MAS, a cardiothoracic surgeon with Keck Medicine and the study&rsquo;s lead author in a <a href="https://www.eurekalert.org/pub_releases/2020-03/uosc-tli032420.php">press release</a>. &ldquo;Previous studies have determined that socioeconomic status plays a role in the surgical management of patients with lung cancer, but we are the first to examine the relationship between socioeconomic status and access to chemotherapy in patients with pN1 disease.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Those living in rural areas, uninsured or on Medicaid less likely to receive recommended lung cancer treatment <a href="https://t.co/I4RjBvhAKq">https://t.co/I4RjBvhAKq</a> <a href="https://t.co/McEJG8La6m">pic.twitter.com/McEJG8La6m</a>
&mdash; Science Codex (@sciencecodex) <a href="https://twitter.com/sciencecodex/status/1242959963015663617?ref_src=twsrc%5Etfw">March 25, 2020</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;&ldquo;It is clear that as medical professionals, we need to find creative solutions to help at-risk populations receive guideline-recommended care,&rdquo; Dr. David added. &ldquo;Lung cancer survival rates are improving and all patients, regardless of where they live or financial status, should be able to take advantage of the treatment that will give them the best chance of recovery and survival.&rdquo;

Jennifer W. Carlisle, MD

Cecilia Brown

Optimizing Amivantamab Treatment: Dr. Carlisle Shares Insights From ASCO 2025 Session

ASCO 2025

Lung Cancers Today Editors

ASCO 2025: TROPION-Lung02 Evaluates Frontline Dato-DXd Plus Pembrolizumab, With or Without Chemotherapy in Advanced NSCLC

Laura Litwin

Phase 2 KRYSTAL-7 Study: First Look at Efficacy, Survival Data of Adagrasib Plus Pembrolizumab

Phase 3 HARMONi Trial Meets PFS Endpoint in EGFR-Mutated NSCLC

Immunotherapy in NSCLC

Coral Olazagasti, MD

ASCO 2025: Dr. Olazagasti on Opportunities for Learning, Hope, and Connection

Conference Coverage

Eric Singhi, MD

ASCO 2025: Dr. Singhi Shares Key Lung Cancer Studies to Watch

Latest News

People Living in Rural Areas, Uninsured or on Medicaid Less Likely to Receive Necessary Lung Cancer Treatment

Non-Small Cell Lung Cancer

Patients living in rural areas or who are on Medicaid or uninsured are less likely to receive chemotherapy for Non-small cell lung cancer (NSCLC), according to a study ...

People Living in Rural Areas, Uninsured or on Medicaid Less Likely to Receive Necessary Lung Cancer